Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 767.96

+2.6%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	10/14/2014 6:28:00 PM
	Read Replies (1) of 3559

Key events for REGN from RBC Capital Markets (high five to DH for the report that was published today). Wow, what a busy agenda for the folks there. Phenomenal pipeline. I really like the prospects for Alirocumab and Dupilumab, and am eager to see the initial results for the CD20 plus CD3 bispecific antibody and for the anti-PDGF mAB/Eylea combination. • Oct. 23, 2014 Eylea BRVO PDUFA • Nov. 2014 Alirocumab (REGN727) Phase III detailed data for LDL-cholesterol lowering at AHA (Nov. 15-19, 2014) • Nov. 20th, 2014 Alirocumab launch discussion at SNY analyst event • YE:14 Eylea, Lucentis, Avastin 1-year Phase III head-to-head data in DME (DRCRN: Protocol T); focus will be on differentiation, if any • 2H:14 REGN1400 Phase I data in cancer • YE:14 Zaltrap Phase III in mCRC after oxaliplatin failure • YE:14 Zaltrap Phase III in mCRC after previous oxaliplatin treatment (AFLAME) • YE:14 Alirocumab (REGN727) BLA and MAA filings; important in terms of getting visibility on the next set of revenue drivers for REGN • YE:14 REGN1500 Phase I safety and tolerability data • YE:14 REGN1193 Phase I data in healthy volunteers • YE:14 CD20-CD3 bi-specific Initiate Phase I • YE:14/ 1H:15 Anti PD-1 Initiate Phase I • YE:14/ 1H:15 Nesvacumab (REGN910) Phase I data in advanced cancers (Nevascumab and Zaltrap) • YE:14/ 1H:15 REGN2222 (SAR438584) Phase I data in healthy volunteers • YE:14/ 1H:15 REGN1033 Phase II data in sarcopenia (loss of muscle mass); potential to show efficacy in a difficult to treat indication • YE:14/ 1H:15 Dupilumab (REGN668) Phase II data in atopic dermatitis; data has been positive so far and expectations are for clean positive results • YE:14/ 1H:15 Eylea + Nesvacumab Phase I single-agent or combination start with Eylea (on clinical hold for oncology) • 1Q:15 Dupilumab (REGN668) Phase II data in moderate-to-severe uncontrolled asthma • 1Q/ 2Q:15 Alirocumab BLA and/ or MAA acceptance for review • 1H:15 REGN2176-3 (Eylea + anti-PDGFR) Phase I data in wet AMD; feasibility of a single injection could help ensure a competitive advantage for the ophthalmology franchise • 1H:15/ Mid-2015 Sarilumab (REGN88) Phase I data in rheumatoid arthritis (sarilumab vs. tocilizumab) • 1H:15/ Mid-2015 Sarilumab Phase III data in rheumatoid arthritis not responding to or intolerant of anti-TNFs (SARIL-RA-TARGET) • 1H:15 Eylea, Lucentis, Avastin Phase III data in DME (POLARIS) • 1H/ Mid-2015 Sarilumab Phase II data in non-infectious uveitis (SARILNIUSATURN) • 1H:15/ 2H:15 Alirocumab Phase III data in patients with heFH or high CV risk • Mid-2015 Alirocumab Phase III data from ODYSSEY CHOICE I • Mid-2015 Alirocumab US approval for BLA; approval expected and sales will add to top line • 3Q/ 4Q:15 AVA-101 Phase II data in wet AMD from partner Avalanche

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next